Restricting the price or the patent and exclusivity awards of medical countermeasures could inhibit manufacturers from investing in the work needed to prepare for future pandemics, Biden administration officials told Congress on 4 May.
The comments came in response to questions from Republican Sen. Bill Cassidy, R-La., the ranking member of the Senate Health...